8-K: RxSight Reports Mixed 2025 Results, Issues Cautious 2026 Outlook

RxSight, Inc. announced its fourth quarter and full year 2025 financial results, showing strong Light Adjustable Lens growth but overall revenue decline and increased net losses, alongside a conservative 2026 guidance.

Summary

• Full-year 2025 global sales decreased 4% to $134.5 million compared to the prior year.
• Light Adjustable Lens (LAL) unit sales increased 12% to 109,615 in 2025, with LAL revenue growing 12%.
• Light Delivery Devices (LDD) system sales decreased 48% in 2025 compared to 2024, with only 163 units sold.
• Gross profit for 2025 was $103.0 million, representing 76.6% of revenue, up from 70.7% in 2024, primarily due to a higher percentage of LAL sales.
• Operating expenses for 2025 increased 11% to $151.2 million, driven by strategic investments in commercial, operational, R&D, and marketing activities.
• Net loss for 2025 widened to $(38.9) million, or $(0.95) per share, compared to $(27.5) million, or $(0.71) per share in 2024.
• Adjusted net loss for 2025 was $(7.3) million, or $(0.18) per share, compared to $(2.8) million, or $(0.07) per share in 2024.
• Fourth quarter 2025 total revenue decreased 19% to $32.6 million, largely due to a 72% decrease in LDD revenue year-over-year.
• Fourth quarter 2025 LAL revenue decreased 1% year-over-year, but sequential LAL procedure growth was 10% compared to Q3 2025.
• Cash, cash equivalents, and short-term investments totaled $228.1 million as of December 31, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to negative report. While LAL adoption and gross margins show strength, the overall revenue decline, widening net losses, and conservative 2026 guidance, particularly concerning LDD sales, indicate significant challenges and a potentially difficult year ahead.

Positives

• Light Adjustable Lens (LAL) unit sales increased 12% year-over-year to 109,615 in 2025, indicating strong adoption.
• Over 300,000 RxSight LAL procedures have been performed since launch, reinforcing clinical benefits.
• The Light Delivery Devices (LDD) installed base expanded to 1,134, providing a foundation for future procedure growth.
• Gross profit margin improved to 76.6% for the full year 2025 (from 70.7% in 2024) and 77.5% for Q4 2025 (from 71.6% in Q4 2024), driven by a favorable shift in product mix towards higher-margin LAL sales.
• FDA Post-approval study results demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs were accepted for publication.
• Regulatory approval was received in Australia, expanding the company's international market opportunity.
• Operating expenses in Q4 2025 decreased 2% year-over-year, partially due to lower personnel costs.

Negatives

• Full-year 2025 global sales decreased 4% to $134.5 million compared to the prior year.
• Light Delivery Devices (LDD) system sales decreased significantly by 48% in 2025 and 72% in Q4 2025 year-over-year.
• Net loss for 2025 widened to $(38.9) million, or $(0.95) per share, from $(27.5) million, or $(0.71) per share in 2024.
• Adjusted net loss for 2025 increased to $(7.3) million, or $(0.18) per share, from $(2.8) million, or $(0.07) per share in 2024.
• Fourth quarter 2025 total revenue decreased 19% to $32.6 million compared to Q4 2024.
• LAL revenue in Q4 2025 decreased 1% year-over-year, despite full-year growth.
• The company's 2026 revenue guidance of $120.0 to $135.0 million reflects lower year-over-year LDD placements, indicating continued headwinds in this segment.
• 2026 gross margin guidance of 70% to 72% is lower than 2025's 76.6%, driven by higher per-unit manufacturing costs associated with lower LDD production volumes.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any future results expressed, implied, or inferred.
• Specific risk factors are detailed in Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date of this press release.

Future Outlook

RxSight provided full-year 2026 financial guidance, projecting revenue between $120.0 million and $135.0 million, reflecting anticipated lower year-over-year Light Delivery Device (LDD) placements. Gross margin is expected to be between 70% and 72%, influenced by higher per-unit manufacturing costs due to lower LDD production volumes. Operating expenses are forecast to range from $150.0 million to $160.0 million, with non-cash stock-based compensation expense estimated at $30.0 million to $32.0 million.

Management Comments

• "Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress."
• "While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company's differentiated therapy."
• "Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients."

Industry Context

StockSavvy.ai notes that RxSight's performance reflects a common challenge in medical device companies with a razor-and-blade model: strong adoption of the consumable (LAL) can be offset by slower sales of the capital equipment (LDD). The expansion into international markets like Australia is a positive strategic move to broaden the addressable market, while the FDA post-approval study results reinforce the clinical differentiation of their core product in the competitive intraocular lens market.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. Therefore, a direct comparison to industry standards based solely on this filing is not possible.

Stakeholder Impact

• Shareholders: May experience negative sentiment due to declining overall revenue, widening losses, and a cautious outlook for 2026, potentially impacting share price.
• Customers (Physicians/Clinics): Continued strong adoption of LAL suggests satisfaction with the core product, but lower LDD sales might indicate market saturation or competitive pressures for new device placements.
• Employees: Strategic investments in commercial and operational footprint, R&D, and marketing suggest continued employment and growth opportunities in these areas, but overall financial performance could create uncertainty.
• Suppliers: Lower LDD production volumes could impact suppliers of components for these devices.

Next Steps

• Host a conference call on February 25, 2026, at 1:30 p.m. Pacific Time to discuss Q4 and full year 2025 financial results and 2026 guidance.
• Continue disciplined execution to support doctors in delivering customized vision solutions.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, with the SEC on or about the date of the press release.

Key Dates

Recommendation

While RxSight demonstrates strong adoption and improved gross margins for its core Light Adjustable Lens product, the significant decline in Light Delivery Device sales and the resulting overall revenue decrease, coupled with widening net losses and a conservative 2026 outlook, present considerable headwinds. The company's cash position provides some stability, and international expansion is a positive, but the immediate financial trajectory suggests caution. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of commercial initiatives and the company's ability to stabilize LDD sales and return to overall revenue growth before considering further investment.

Keywords

RxSight, RXST, Light Adjustable Lens, LAL, Light Delivery Device, LDD, Cataract Surgery, Ophthalmic Medical Device, Financial Results, 2025 Earnings, 2026 Guidance, IOL, Intraocular Lens, Medical Technology, FDA Approval, Australia Regulatory Approval